Fenofibrate — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hyperlipidemia

• Atorvastatin
• Ezetimibe
• Gemfibrozil
• Lovastatin
• Pravastatin
• Rosuvastatin
• Simvastatin

Other medications in Heart & Cardiovascular

• Flecainide
• Fluvastatin
• Fosinopril
• Furosemide
• Hydralazine
• Hydrochlorothiazide
• Icosapentaenoic Acid
• Iloprost

About Fenofibrate

Fenofibrate is a widely prescribed medication used to manage high levels of cholesterol and triglycerides, crucial for cardiovascular health. Understanding its role is key, and with TheDrugClub, accessing this important medication becomes remarkably affordable. Fenofibrate is a powerful medication primarily used to help individuals manage and reduce dangerously high levels of fats in their blood, specifically triglycerides and cholesterol. It's often prescribed when diet, exercise, and lifestyle changes alone aren't enough to bring these levels into a healthy range. ### What Fenofibrate Treats

Fenofibrate is commonly prescribed for conditions such as hypertriglyceridemia (very high triglycerides) and primary hypercholesterolemia (high cholesterol). High triglycerides can increase the risk of pancreatitis, a serious inflammation of the pancreas, while elevated cholesterol, particularly LDL ("bad" cholesterol), contributes to the buildup of plaque in arteries, leading to atherosclerosis, heart disease, and stroke. Fenofibrate helps to lower these harmful fats and can also slightly increase levels of HDL ("good" cholesterol), further supporting cardiovascular health. ### How Fenofibrate Works

Belonging to a class of drugs called fibrates, fenofibrate works by activating a natural receptor in the body known as peroxisome proliferator-activated receptor alpha (PPAR-alpha). When activated, PPAR-alpha plays a critical role in regulating the metabolism of fats. This activation leads to several beneficial effects:

• Decreased Triglyceride Production: Fenofibrate helps reduce the liver's production of very low-density lipoprotein (VLDL), which is the primary carrier of triglycerides in the blood. * Increased Triglyceride Removal: It enhances the activity of an enzyme called lipoprotein lipase, which breaks down triglycerides, effectively clearing them from the bloodstream. * Improved Cholesterol Profile: While its main action is on triglycerides, fenofibrate can also help lower LDL cholesterol and increase HDL cholesterol. By targeting these pathways, fenofibrate helps to restore a healthier balance of fats in the blood, reducing the risk of associated health complications. ### Typical Costs of Fenofibrate

Without insurance, the cost of generic fenofibrate can vary significantly depending on the pharmacy, dosage, and quantity. A month's supply might range from $15 to $50 or more. Brand-name versions, such as Tricor or Trilipix, are substantially more expensive, often costing hundreds of dollars per month. Even with insurance, many patients face co-pays that can range from $10 to $

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Fenofibrate is approved for (FDA label)

Fenofibrate tablets are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fenofibrate (FDA label)

Fenofibrate Tablets: 48 mg: Yellow coloured, oval shaped, biconvex film coated tablets, debossed with ‘Cipla’ on one side and code ‘459’ on other side. 145 mg: White to off white coloured, oval shaped, biconvex film coated tablets, debossed with ‘Cipla’ on one side and code ‘458’ on other side. Tablets: 48 mg and 145 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fenofibrate (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Mortality and coronary heart disease morbidity [see Warnings and Precautions (5.1) ] Hepatoxicity [see Warnings and Precautions (5.2) ] Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.3) ] Increases in Serum Creatinine [see Warnings and Precautions (5.4) ] Cholelithiasis [see Warnings and Precautions (5.5) ] Increased Bleeding Risk with Coumarin Anticoagulants [see Warnings and Precautions (5.6) ] Pancreatitis [see Warnings and Precautions (5.7) ] Hematologic Changes [see Warnings and Precautions (5.8) ] Hypersensitivity reactions [see Warnings and Precautions (5.9) ] Venothromboembolic disease [see Warnings and Precautions (5.10) ] Paradoxical Decreases in HDL Cholesterol Levels [see Warnings and Precautions (5.11) ] Adverse reactions (≥ 2% and greater than placebo): abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis (6.1) . To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fenofibrate (FDA label)

Fenofibrate is contraindicated in patients with: Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis [see Clinical Pharmacology (12.3) ]. Active liver disease, including those with unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2) ]. Pre-existing gallbladder disease [see Warnings and Precautions (5.5) ]. Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate [see Warnings and Precautions (5.9) ]. Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis (4). Active liver disease including those with unexplained persistent liver function abnormalities (4). Pre-existing gallbladder disease (4). Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate tablets (4) .

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fenofibrate (FDA label)

Hepatotoxicity: Serious drug-induced liver injury, including liver transplantation and death, has been reported with fenofibrates, including fenofibrate tablets. Monitor patient’s liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy. Discontinue if signs or symptoms of liver injury develop or if elevated enzyme levels persist (5.2). Myopathy and Rhabdomyolysis: Have been reported in patients taking fenofibrates. Risks are increased during co-administration with a statin, in geriatric patients, and in patients with renal impairment or hypothyroidism. Discontinue fenofibrate if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Temporarily discontinue fenofibrate in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the fenofibrate dosage.

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fenofibrate (FDA label)

Table 2 presents clinically important drug interactions with fenofibrate. Table 2. Clinically Important Drug Interactions with fenofibrate Statins Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins. Intervention: Consider if the benefit of using fenofibrate concomitantly with statin therapy outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis, have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with fenofibrate outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of colchicine.

Source: FDA prescribing information (DailyMed). Set ID: c870ea48-5dde-4a6f-9ddb-56b494bb2b55. SPL document ID: d44a64dc-52e9-4cd0-b173-70c97a0d524c. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.